Business
Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence
BILLERICA, Mass., December 22, 2025--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix’s ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay, is the largest population-based assessment of Alzheimer’s Disease Neuropathological Changes (ADNC) to date, provi
About this update from Quanterix Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/deee1255e61cb58cc9cd962cafa2db99"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.yfQ0XoEnVvk_Nj05TauOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/deee1255e61cb58cc9cd962cafa2db99","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/K1pmdi6WnoQnfWbKC1gs1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/deee1255e61cb58cc9cd962cafa2db99","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"BILLERICA, Mass., December 22, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix’s ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay, is the largest population-based assessment of Alzheimer’s Disease Neuropathological Changes (ADNC) to date, providing crucial, scalable data to redefine disease prevalence.","length":576,"tagName":"p"},{"type":"text","content":"The research, conducted on a Norwegian population-based cohort of over 11,000 individuals aged 58 and above, addresses a long-standing challenge in epidemiology: obtaining accurate ADNC prevalence data from a representative general population rather than smaller, clinic-based samples. The study found that prevalence of ADNC rises sharply from 10% in individuals aged 58-69.9 years to 64.9% in those over 90. Furthermore, the findings suggest a higher prevalence of AD dementia in older individuals than previously estimated and enable more confident identification of asymptomatic individuals with ADNC who may benefit from early intervention or clinical trial participation.","length":677,"tagName":"p"},{"type":"text","content":""For decades, accurately mapping...